SWOG S0910: A Phase 2 Trial of Clofarabine/Cytarabine/Epratuzumab for Relapsed/Refractory Acute Lymphocytic Leukaemia

Precursor B-acute lymphoblastic leukaemias (pre-B ALLs) comprise the majority of ALLs and virtually all blasts express CD22 in the cytoplasm and on the cell surface. In the present study (Southwestern Oncology Group S0910), we evaluated the addition of epratuzumab, a humanized monoclonal antibody ag...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Advani, Anjali S., McDonough, Shannon, Coutre, Steven, Wood, Brent, Radich, Jerald, Mims, Martha, O’Donnell, Margaret, Elkins, Stephanie, Becker, Michael, Othus, Megan, Appelbaum, Frederick R.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2014
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4209396/
https://ncbi.nlm.nih.gov/pubmed/24579885
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.12778
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi